Dr. James Jaquith is the Head of Medicinal Chemistry at The Centre for Drug Research and Development (CDRD), Canada’s national translational and commercialization centre. CDRD plays a key role in the evaluation, funding, de-risking, and strategic development of academic research programs from Canadian investigators. Current in-house programs focus on novel approaches for the treatment of rare genetic diseases, fibrotic and inflammatory conditions, pathogenic infections, peripheral neuropathies, diabetes, Parkinson’s disease, and cancer, with a special focus on novel ADC platforms.
Dr. Jaquith also leads CDRD’s Regenerative Medicine, Inflammation and Fibrosis Task Force which specifically seeks to identify research projects that are at the cutting edge of the Regenerative Medicine field. Our primary focus is on the development of small molecule, antibody and antibody drug conjugate therapies for the treatment of inflammatory and fibrotic diseases.
Prior to joining CDRD, Dr. Jaquith was the Director of Chemistry at Aegera Therapeutics (Pharmascience Inc.) where he made important contributions to the discovery and development of several clinical development candidates which advanced into clinical trials. Dr. Jaquith received his B.Sc. and M.Sc. in Chemistry from the University of Waterloo, and a Ph.D. from the University of Ottawa, before joining Apoptogen Inc. as an NSERC Industrial Research Fellow.